Skip to content
Menu

UroGen Pharma Shares Results From 5-Year Follow-Up Study On Olympus

Benzinga Newsdesk 3 weeks ago

FDANews

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTOResults demonstrate sustained disease control through extended follow-up among

  • Five-year Olympus follow-up data published in Therapeutic Advances in Urology reinforce the long-term durability of response with JELMYTO
  • Results demonstrate sustained disease control through extended follow-up among patients who achieved a complete response after treatment with JELMYTO
  • No progression to high-grade disease was observed during extended follow-up

Read at benzinga.com

← All stock news